|
Age (years), mean (SD)
|
61 (12)
|
59 (12)
|
|
Female patients, n (%)
|
27 (84)
|
19 (86)
|
|
Duration of follow up (days), median (IQR)
|
491 (386,603)
|
506 (390,648)
|
|
Ever smokers, n (%)
|
10 (31)
|
6 (27)
|
|
Aetiology, n (%)
|
Post-infectious: 16 (50)
|
Post-infectious: 13 (59)
|
|
Idiopathic: 11 (34)
|
Idiopathic: 5 (23)
|
|
Rheumatological: 2 (6)
|
Rheumatological: 1 (4)
|
|
Other: 3 (9)
|
Other: 3 (14)
|
|
Bhalla score, mean (SD)
|
12 (9)
|
12 (9)
|
|
Number of lobes involved, median (IQR)
|
3.5 (2,5)
|
3.5 (2,5)
|
|
BSI score, median (IQR)
|
8.5 (4,12.8)
|
9 (4.5,11.3)
|
|
Severity (BSI classification), n (%)
|
Mild: 9 (28)
|
Mild: 6 (27)
|
|
Moderate: 8 (22)
|
Moderate: 4 (18)
|
|
Severe: 15 (50)
|
Severe: 12 (55)
|
|
Self-reported exacerbation frequency in previous year, median (IQR)
|
3 (2,5.8)
|
3 (2.3,6)
|
|
Asthma diagnosis, n (%)
|
7 (22)
|
6 (27)
|
|
Previous pseudomonas on sputum culture, n (%)
|
7 (22)
|
5 (23)
|
|
Previous hospitalisation, n (%)
|
9 (28)
|
8 (36)
|
|
Treatment details (all given as n (%))
|
|
Short-acting inhaled bronchodilator
|
13 (41)
|
10 (45)
|
|
Long-acting inhaled bronchodilator
|
12 (38)
|
8 (36)
|
|
Inhaled corticosteroid use
|
16 (50)
|
11 (50)
|
|
Long term macrolide therapy, n (%)
|
2 (6)
|
2 (9)
|
|
Lung function measurements: (all given as mean (SD))
|
|
FEV1(L), mean (SD)
|
1.96 (0.90)
|
2.02 (0.95)
|
|
FEV1% predicted (SD)
|
78 (26)
|
76 (28)
|
|
FEV1/FVC ratio, (SD)
|
0.71 (0.15)
|
0.71 (0.17)
|
|
Stable PEFR (L/min), (SD)
|
334 (104)
|
337 (110)
|
|
PEFR variability, % best (see text)
|
12.4 (8.2)
|
13.8 (9.4)
|
|
SGRQ and CAT scores (all given as mean (SD))
|
|
Symptoms
|
48.8 (24.3)
|
50.2 (26.1)
|
|
Activity
|
40.3 (27.8)
|
41.8 (27.7)
|
|
Impact
|
27.2 (16.5)
|
29.4 (14.9)
|
|
Total SGRQ score
|
34.8 (18.1)
|
37.6 (16.9)
|
|
CAT score
|
16.6 (7.0)
|
17.2 (7.1)
|
